| Literature DB >> 25412843 |
Makoto Endo1, Marieke A de Graaff2, Davis R Ingram3, Simin Lim4, Dina C Lev3, Inge H Briaire-de Bruijn2, Neeta Somaiah5, Judith V M G Bovée2, Alexander J Lazar6, Torsten O Nielsen4.
Abstract
New York esophageal squamous cell carcinoma 1 (NY-ESO-1, CTAG1B) is a cancer-testis antigen and currently a focus of several targeted immunotherapeutic strategies. We performed a large-scale immunohistochemical expression study of NY-ESO-1 using tissue microarrays of mesenchymal tumors from three institutions in an international collaboration. A total of 1132 intermediate and malignant and 175 benign mesenchymal lesions were enrolled in this study. Immunohistochemical staining was performed on tissue microarrays using a monoclonal antibody for NY-ESO-1. Among mesenchymal tumors, myxoid liposarcomas showed the highest positivity for NY-ESO-1 (88%), followed by synovial sarcomas (49%), myxofibrosarcomas (35%), and conventional chondrosarcomas (28%). Positivity of NY-ESO-1 in the remaining mesenchymal tumors was consistently low, and no immunoreactivity was observed in benign mesenchymal lesions. On the basis of these findings, nearly 90% of myxoid liposarcomas, as well as a significant proportion of synovial sarcomas, myxofibrosarcomas, and conventional chondrosarcomas are good candidates for immunotherapy targeting NY-ESO-1.Entities:
Mesh：
Substances：
Year: 2014 PMID： 25412843 DOI： 10.1038/modpathol.2014.155
Source DB: PubMed Journal: Mod Pathol ISSN： 0893-3952 Impact factor: 7.842